Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...

Private Advisor Group LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 38.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00. The company’s shares closed yesterday at $133.43.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...